Skip to main content
. 2022 Mar 21;298(5):101852. doi: 10.1016/j.jbc.2022.101852

Figure 5.

Figure 5

Effects of Lusianthridin in β1/2 double KO (DKO) U2OS cells stably expressing β1 or β2 WT and β1 or β2 S108A.A, Western blot analysis of β1/2 DKO cells stably expressing β1 or β2 WT and β1 or β2 S108A using the indicated antibodies. B–D, pACC HTRF analysis of stable cell lines expressing β1 or β2 WT and β1 or β2 S108A treated with AICAR (B), A-769662 (C), or Lusianthridin (D). Results are presented as the fold increase in pACC HTRF signal and are means ± SEM of at least three independent experiments. E, Western blot analysis of β1 WT and β1 S108A stable cell lines treated with Lusianthridin using the indicated antibodies. Quantification of three independent experiments is shown as a ratio of the signal of pACC/ACC, along with a representative blot. AICAR, 5-aminoimidazole-4-carboxamide riboside; HTRF, Homogenous Time-Resolved Fluorescence; pACC, phospho-ACC.